PITUITARY OVARIAN SUPPRESSION BY THE STANDARD AND HALF-DOSES OF D-TRP-6-LUTEINIZING HORMONE-RELEASING HORMONE DEPOT

被引：27

作者：

BALASCH, J

GOMEZ, F

CASAMITJANA, R

CARMONA, F

RIVERA, F

VANRELL, JA

机构：

[1] Department of Obstetrics and Gynaecology, Faculty of Medicine, Hospital Clínic i Provincial, 08036-Barcelona

[2] Hormonal Laboratory, Faculty of Medicine, Hospital Clínic i Provincial, 08036-Barcelona

来源：

HUMAN REPRODUCTION | 1992年 / 7卷 / 09期

关键词：

D-TRP-6-LHRH; DEPOT ADMINISTRATION; PITUITARY DESENSITIZATION; STANDARD AND HALF-DOSES;

D O I：

10.1093/oxfordjournals.humrep.a137832

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

A total of 20 women with regular menstrual cycles and normal ovulatory function were randomized to receive 3.75 mg or 1.87 mg of D-Trp-6-luteinizing hormone-releasing hormone (LHRH) in microcapsules either in the early follicular phase (day 2) or during the mid-luteal phase (day 21) of the menstrual cycle. Pituitary - ovarian function was studied by sequential plasma measurements of oestradiol, follicle stimulating hormone, luteinizing hormone and progesterone. Our results show that the full, standard dose (3.75 mg) of D-Trp-6-LHRH depot and the half-dose (1.87 mg) were equally effective in their desensitizing action, and that desensitization occurs more rapidly with early follicular phase administration of the analogue.

引用

页码：1230 / 1234

页数：5

共 21 条

[1] Bramley T.A., Menzies G.S., Baird D.T., Specific binding of gonadotrophin-releasing hormone and an agonist to human corpus luteum homogenates: Characterization, properties, and luteal phase levels, J. Clin. Endocrinol. Metab, 6, pp. 834-841, (1985)
[2] Caspi E., Ron-El R., Gdan A., Nachum A., Herman A., Softer Y., Weinraub Z., Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog d-Trp-6-luteinizing hormone-releasing hormone and gonadotropins, Fertil. Steril, 51, pp. 95-99, (1989)
[3] Conn P.M., Crowley W.F., Gonadotropin-releasing hormone and its analogues, N. Engl. J. Med, 32, pp. 93-103, (1991)
[4] Dahl K.D., Pavlou S.N., Kovacks W.J., Hsueh A.J.W., The changing ratio of serum bioactive to immunoreactive follicle-stimulating hormone in normal men following treatment with a potent gonadotropin releasing hormone antagonist, J. Clin. Endocrinol. Metab, 63, pp. 792-794, (1986)
[5] Hsueh A.J.W., Erickson G.F., Extrapituitary action of gonadotrophin-releasing hormone: Direct inhibition of ovarian steroidogenesis, Science, 20, pp. 854-855, (1979)
[6] Loumaye E., The control of endogenous secretion of LH by gonadotropin-releasing hormone agonists during ovarian hyperstimula tion for in vitro fertilization and embryo transfer. Hum, Reprod, 5, pp. 357-376, (1990)
[7] Loumaye E., Coen G., Pampfer S., Vankrieken L., Thomas K., Use of gonadotropin-releasing hormone agonist during ovarian stimulation leads to significant concentration of peptide in follicular fluids. Fertil, Steril, 52, pp. 256-263, (1989)
[8] Mann D.R., Gould K.G., Collins D.C., Influence of continuous gonadotropin-releasing hormone (GnRH) agonist treatment on luteinizing hormone and testosterone secretion, the response to GnRH, and the testicular response to human chorionic gonadotropin in rhesus monkeys, J. Clin. Endocrinol. Metab, 58, pp. 262-267, (1984)
[9] Meldrum D.R., Chang R.J., Lu J., Vale W., Rivier J., Judd H.L., Medical oophorectomy, J. Clin. Endocrinol. Metab, 54, pp. 1081-1083, (1982)
[10] Meldrum D.R., Tsao Z., Monroe S.E., Braunstein G.D., Sladek J., Lu J.K.H., Vale W., Rivier J., Judd H.L., Chang R.J., Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women, J. Clin. Endocrinol. Metab, 58, pp. 755-757, (1984)

← 1 2 3 →